NASDAQ · Analyst Forecast

Alnylam Pharmaceuticals, Inc. (ALNY) Stock Forecast & Price Target

$159.76 NASDAQ: ALNY Market Cap $21.40B

Price as of Nov 16, 2026 (intraday, delayed) · Analyst estimates retrieved Nov 16, 2026 · Source: Financial Modeling Prep (analyst estimates) (methodology)

Revenue and earnings estimates published by analysts covering Alnylam Pharmaceuticals, Inc. (ALNY), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.

For Alnylam Pharmaceuticals, Inc., analysts forecast revenue rising from $3.75B in 2025 to $9.71B in 2030; the average estimate for 2030 earnings per share is $14.41; with published estimates ranging from $12.66 to $17.25; 23 analysts contribute to these figures. These are forecasts published by analysts, not results.

Analyst price targets

MeasureValue
Current priceWhat the share trades at now.$159.76
Consensus targetThe average of the price targets analysts have published.$331.93
Median targetThe middle target, less affected by a single outlier.$322.00
Highest targetThe most optimistic published target.$455.00
Lowest targetThe most pessimistic published target.$225.00
Difference from priceHow far the consensus target sits from today’s price.+107.8%

A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.

Revenue forecast (USD)

The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.

YearLowAverageHighAnalysts
2025$3.69B$3.75B$3.88B18
2026$5.40B$5.44B$5.50B21
2027$6.12B$6.57B$7.94B22
2028$6.23B$7.70B$9.78B23
2029$7.92B$8.74B$10.06B12
2030$8.80B$9.71B$11.18B11

Earnings per share forecast

YearLowAverageHighAnalysts
2025$1.39$2.46$3.1818
2026$8.12$18.42$22.6021
2027$7.19$8.96$11.0122
2028$5.24$11.19$27.4623
2029$10.87$12.38$14.8112
2030$12.66$14.41$17.2511

Alnylam Pharmaceuticals, Inc. (ALNY) forecast — frequently asked questions

What is the analyst price target for Alnylam Pharmaceuticals, Inc.?

Analysts covering Alnylam Pharmaceuticals, Inc. (ALNY) have a consensus price target of $331.93, 107.8% above the current price of $159.76. Published targets range from $225.00 to $455.00. A price target is a forecast, not a measure of value, and targets are revised often.

What are analysts forecasting for Alnylam Pharmaceuticals, Inc.'s earnings?

The average analyst estimate for Alnylam Pharmaceuticals, Inc. (ALNY) earnings per share in 2030 is 14.41, with individual estimates between 12.66 and 17.25.

How much revenue is Alnylam Pharmaceuticals, Inc. expected to make?

Analysts forecast Alnylam Pharmaceuticals, Inc. (ALNY) revenue of $9.71B in 2030, based on 11 published estimates.

How many analysts cover ALNY?

23 analysts contribute estimates for Alnylam Pharmaceuticals, Inc. (ALNY). Thin coverage makes an average less reliable.

Analyst forecasts for other Biotechnology stocks

VRTX forecastREGN forecastMRNA forecastRVMD forecastROIV forecastINSM forecastUTHR forecastINCY forecastASND forecastEXEL forecastAll Biotechnology stocks

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.